Items Tagged ‘trastuzumab’

December 12th, 2017

Keytruda Immunotherapy Shows Promise for Patients With Herceptin-resistant Breast Cancer

By

A combination of Keytruda (pembrolizumab) and Herceptin (trastuzumab), tested in patients with Herceptin-resistant advanced HER2-positive breast cancer, was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker for Keytruda, according to data presented at the 2017 San Antonio Breast Cancer Symposium. About HER2-Positive Breast Cancer About one in five […]

View full entry

Tags: Breast Cancer, Herceptin-resistant, immunotherapy, keytruda, News, pembrolizumab, Precision Cancer Medicine, SABCS, trastuzumab


November 1st, 2017

Nerlynx Modestly Improves Survival of HER 2-Positive Early Stage Breast Cancer

By

Positive results from the clinical trial evaluating neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer following trastuzumab-based therapy (ExteNET trial) were presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. About HER2-Positive Breast Cancer Approximately 20% to 25% of breast cancers over-express the HER2 protein. HER2-positive […]

View full entry

Tags: Breast Cancer, HER-2, HER4 Positive Early Stage Breast Cancer, herceptin, Nerlynx HER1, News, Precision Cancer Medicine, trastuzumab


May 11th, 2016

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer

By

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). These results were recently published in The Lancet Oncology. The HER2 receptor is a protein that is normally found on the surface of several different types of cells […]

View full entry

Tags: Colon Cancer, colorectal cancer, HER2-positive, herceptin, lapatinib, News, Rectal Cancer, trastuzumab, Tykerb


March 24th, 2015

Herceptin Superior to Tykerb for Treatment of HER2-positive Breast Cancer

By

In patients with human epidermal growth factor receptor (HER2)–positive advanced breast cancer, the combination of Herceptin® (trastuzumab) plus a taxane resulted in delayed time to cancer progression and was associated with fewer side effects than Tykerb® (lapatinib) plus a taxane, according to final clinical trial results reported in the Journal of Clinical Oncology. The HER2 […]

View full entry

Tags: Breast Cancer, HER2, herceptin, lapatinib, Metastatic Breast Cancer, News, Stages II-III Breast Cancer, trastuzumab, Tykerb